The new face of pharma: Partner, Investor, Acquirer…Friend?

Big pharma makes big bucks. It saves lives, develops treatments, pushes the boundaries of humanity.\r\nBut problems are flying at pharma from all angles. Drug development costs are soaring, the war for talent shows no signs of abating. Pharma finds itself in something of an identity crisis. What should big pharma be in 2024? Is it a partner? An investor? Acquirer? A friend? Or something entirely different?